EverSource Wealth Advisors’s Fulcrum Therapeutics FULC Stock Holding History

EverSource Wealth Advisors’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84K	Buy	504 +95	+23%	+$578	﹤0.01%	3752
2026 Q1	$3.14K	Buy	409 +202	+98%	+$1.87K	﹤0.01%	3479
2025 Q4	$2.34K	Buy	207 +3	+1%	+$31	﹤0.01%	3448
2025 Q3	$1.88K	Sell	204 -14	-6%	-$101	﹤0.01%	3536
2025 Q2	$1.5K	Buy	+218	New	+$1.17K	﹤0.01%	3601

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EverSource Wealth Advisors's FULC Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Fulcrum Therapeutics (FULC) stake by 23% in Q2 2026, buying an estimated $578 and bringing the position to 504 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #3752.

EverSource Wealth Advisors first reported a position in FULC in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.14K in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

EverSource Wealth Advisors held 504 shares of Fulcrum Therapeutics worth $1.84K as of Q2 2026.
EverSource Wealth Advisors bought 95 Fulcrum Therapeutics shares in Q2 2026, an estimated $578.
Fulcrum Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3752 holding.
EverSource Wealth Advisors first reported a position in Fulcrum Therapeutics in Q2 2025 and has held it in 5 quarters since.
EverSource Wealth Advisors's Fulcrum Therapeutics position peaked at $3.14K in Q1 2026.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.